Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $32.2 million.

  • GeneDx Holdings' Cost of Revenue rose 1091.75% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.1 million, marking a year-over-year increase of 1274.27%. This contributed to the annual value of $111.1 million for FY2024, which is 133.88% down from last year.
  • As of Q3 2025, GeneDx Holdings' Cost of Revenue stood at $32.2 million, which was up 1091.75% from $31.8 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Cost of Revenue registered a high of $77.7 million during Q4 2022, and its lowest value of $25.0 million during Q1 2024.
  • For the 5-year period, GeneDx Holdings' Cost of Revenue averaged around $42.4 million, with its median value being $31.8 million (2025).
  • As far as peak fluctuations go, GeneDx Holdings' Cost of Revenue surged by 5133.44% in 2021, and later crashed by 6567.28% in 2023.
  • Over the past 5 years, GeneDx Holdings' Cost of Revenue (Quarter) stood at $60.6 million in 2021, then grew by 28.16% to $77.7 million in 2022, then tumbled by 65.67% to $26.7 million in 2023, then rose by 10.39% to $29.4 million in 2024, then rose by 9.45% to $32.2 million in 2025.
  • Its last three reported values are $32.2 million in Q3 2025, $31.8 million for Q2 2025, and $28.6 million during Q1 2025.